Korten V, Tomayko J F, Murray B E
Department of Internal Medicine, University of Texas Medical School, Houston 77030.
Antimicrob Agents Chemother. 1994 Mar;38(3):611-5. doi: 10.1128/AAC.38.3.611.
The in vitro activity of DU-6859a (DU), a new fluoroquinolone agent, was evaluated against 233 gram-positive cocci and was compared with those of ciprofloxacin, vancomycin, nafcillin, and ampicillin. The MICs of DU for 90% of the staphylococci tested were < or = 0.06 microgram/ml. All of the groups A and B and viridans group streptococci were inhibited by < or = 0.125 microgram of DU per ml, which was 32-fold more active than ciprofloxacin. On the basis of MICs for 90% of the strains tested, DU was 32- and 16-fold more active than ciprofloxacin against Enterococcus faecalis and Enterococcus faecium, respectively. The bactericidal activity of DU was demonstrated by time-kill techniques against all ciprofloxacin-susceptible enterococci. DU shows promise for the treatment of infections with gram-positive cocci and warrants further evaluation by in vitro and in vivo studies.
对新型氟喹诺酮类药物DU-6859a（DU）针对233株革兰氏阳性球菌的体外活性进行了评估，并与环丙沙星、万古霉素、萘夫西林和氨苄西林的活性进行了比较。DU对90%受试葡萄球菌的最低抑菌浓度（MIC）≤0.06微克/毫升。所有A组和B组链球菌以及草绿色链球菌均被每毫升≤0.125微克的DU所抑制，其活性比环丙沙星高32倍。根据对90%受试菌株的MIC，DU对粪肠球菌和屎肠球菌的活性分别比环丙沙星高32倍和16倍。通过时间杀菌技术证明DU对所有对环丙沙星敏感的肠球菌具有杀菌活性。DU在治疗革兰氏阳性球菌感染方面显示出前景，值得通过体外和体内研究作进一步评估。
